<DOC>
	<DOCNO>NCT01358331</DOCNO>
	<brief_summary>This study safety , tolerability , efficacy MK-8353 ( formerly SCH 900353 ) give single agent oral therapy participant advance solid tumor do two part . In Part 1a , dose escalation find preliminary maximum tolerate dose ( MTD ) , Part 1b , dose confirmation find recommended Phase 2 dose ( RPTD ) use Part 2 study . In Part 2 study , participant certain type metastatic melanoma metastatic colorectal cancer treat see MK-8353 effective single agent therapy .</brief_summary>
	<brief_title>A Study Safety , Tolerability , Efficacy MK-8353 Participants With Advanced Solid Tumors ( MK-8353-001 )</brief_title>
	<detailed_description />
	<criteria>Pathologically/histologically confirm solid tumor ( metastatic locally advanced disease ) fail respond standard therapy , progress despite standard therapy , standard therapy exist . Participants childbearing potential must negative pregnancy test ; female male must agree use effective contraception course trial 90 day stop study drug . For Part 1b Part 2 , participant metastatic melanoma metastatic colorectal cancer least one measurable lesion Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 life expectancy â‰¥3 month . Adequate organ function . Unstable progressing central nervous system ( CNS ) metastasis unless asymptomatic 3 month , need steroid antiseizure medication . Active gastrointestinal disease disorder history surgery significantly alter gastrointestinal motility absorption . Has recover previous therapy chemotherapy , biologic , hormonal therapy within 4 week study enrollment . Radiation therapy ( except palliative radiation bone lesion ) within 4 week study enrollment . More 3 prior regimen chemotherapy , biologic therapy , hormonal therapy , investigational drug include adjuvant neoadjuvant treatment . Clinically relevant cardiovascular , hepatic , neurologic , endocrine , major systemic disease . Mean QTcF interval ( interval electrocardiogram correct heart rate use Fridericia 's correction ) &gt; 450 msec baseline . Known Human Immunodeficiency Virus ( HIV ) infection , hepatitis infection , tuberculosis infection . Current participation interventional clinical study . History significant eye disease , include glaucoma , retinopathy , retinal vein occlusion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>